T

Texas Center for Drug Development | Houston, TX

Research site
(Unclaimed)
Location
6550 Mapleridge Street, Suite 201, Houston, Texas, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

5 of 29
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat...

Enrolling
Migraine
Medication Overuse Headache
Drug: Placebo
Drug: Eptinezumab

The purpose of this study is to generate sufficient safety, reactogenicity, and immunogenicity data to enable selection of an mRNA-1083 vaccine compo...

Active, not recruiting
Influenza
SARS-CoV-2
Biological: mRNA-1083.1
Biological: mRNA-1010

This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...

Enrolling
SARS-CoV-2
Biological: mRNA-1273.214
Biological: mRNA-1273.815

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Enrolling
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Obicetrapib

Study of the contraceptive efficacy, cycle control, safety, and tolerability of MR-100A-01 in approxmiately 1200 women for up to 13 cycles

Active, not recruiting
Contraception
Drug: MR-100A-01

Trial conditions

Migraine Disorders (6 trials)
Type 2 Diabetes Mellitus (4 trials)
Binge-Eating Disorder (3 trials)
Bulimia (3 trials)
Depression (3 trials)
Depressive Disorder (3 trials)
Feeding and Eating Disor... (3 trials)
Major Depressive Disorder (3 trials)
COVID-19 (2 trials)
Cardiovascular Diseases (2 trials)

And 17 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems